$CBIS Accepted To Present at ICAR 2015

COLORADO SPRINGS, Colo., April 22, 2015 /PRNewswire/ — Cannabis Science, Inc. (CBIS), a U.S. company specializing in the development of cannabis-based medicine and related consulting, is pleased to announce the acceptance of its presentation next month at the 28^th International Conference on Antiviral Research (ICAR) in Rome, Italy.

“We are happy to see this important conference supporting and enabling exposure to the scientific community of the prospective health benefits that cannabinoids have in diseases such as HIV and AIDS,” stated Roscoe M. Moore, Jr., D.V.M., Ph.D., D.Sc., Assistant U.S. Surgeon General (Retired), Special Senior Advisor to Cannabis Science, Inc.

“The Company’s presentation at ICAR in Rome provides more validation of our scientific approach to cannabinoid-based drug development, particularly in the context of the HIV pandemic, and highlights the acumen of our first class team of experts,” said Raymond C. Dabney, Co-Founder, President and CEO of Cannabis Science, Inc.

The peer-reviewed presentation accepted by the ICAR conference committee is a review of peer-reviewed literature finding numerous benefits of cannabinoids in Kaposi sarcoma and HIV. The “poster” concludes that “[f]urther research on the clinical utility and consequences of cannabinoids is necessary to identify new opportunities for cannabinoid-based drug development for HIV patients to target insults to endothelial and microglial cells. Further research on cannabinoids is anticipated in addressing HIV-associated neurocognitive disorder, suppressing inflammatory cytokines and latent pools of resting viremia in macrophages and other cell lines that are currently representing global challenges to HIV eradication.”

The International Conference on Antiviral Research, which takes place on May 11 to May 15, 2015 at the Parco dei Principi Hotel in Rome, Italy, is an annual gathering of biologists, chemists and clinicians interested in antiviral therapeutic and prevention agent research and development. ICAR is sponsored by the International Society of Antiviral Research. Topics discussed at the conference include: medicinal chemistry, virus replication, host cell-virus interactions, virus latency, new target identification, biochemistry and mechanism of action, mechanisms of viral drug resistance, assay development, in vitro evaluation, animal models, pharmacokinetics, toxicology, and clinical trials.

About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions.  The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus:  CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward-looking statements.  Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties.  These forward-looking statements may be impacted, either positively or negatively, by various factors.  Information concerning potential factors that could affect the company are detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.

Cannabis Science, Inc.
Mr. Derwin A. Wallace
Finance & Investor Relations
info@cannabisscience.com
Tel: 1.888.889.0888
Direct: 1.404.500.4950

Mr. Raymond C. Dabney
President & CEO, Co-Founder
info@cannabisscience.com
Tel: 1.888.889.0888